Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user shared their positive experience with Roots by GA, a company that creates personalized hair loss treatments based on DNA analysis, which confirmed their inability to tolerate finasteride. The user is satisfied with their progress 30 days after a hair transplant and the customized formula they received.

There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

RU58841 and pyrilutamide are discussed as alternatives to 5AR blockers for hair loss, with mixed opinions on their safety and effectiveness. Some users report positive experiences with RU58841, while others express concerns about its safety.

The conversation discusses skepticism about the effectiveness of PP405 for hair loss, with users mentioning treatments like dutasteride, oral minoxidil, clascoterone, and upcoming drugs like breezula and long-release oral minoxidil. Some users express hope for future treatments like vdphl01 and amplifica, while others debate the effectiveness and side effects of current options.

PP405 and JXL069 are confirmed to be the same molecule, leading to disappointment due to poor hair regrowth results. Users express skepticism about the credibility of Pelage and the effectiveness of JXL069.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

PP405 and JXL-069 are the same compound, but users experienced no results due to flawed application methods. The topical gel formulation of PP405 is designed to target hair follicle stem cells effectively, unlike liquid solutions that fail to penetrate deeply.

PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

PP405 is being discussed as a promising hair loss treatment, potentially effective when combined with minoxidil and pyrilutamide. Some users are skeptical about rapid hair regrowth claims, while others are considering alternatives like GT20029 and pyrilutamide instead of finasteride.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

The conversation discusses Dr. Blake Bloxham's experiment with Verteporfin for hair loss, with one person suggesting more doctors should try it as it seems beneficial. Another comment notes that results at 4-5 months were not very impressive.

The conversation discusses finding a PG-free solvent for dissolving RU58841 in the UK, with glycerin suggested as a potential alternative. Water is also mentioned as a possible option.

RU58841's potential side effects, particularly heart palpitations, are debated, with some attributing them to contamination with minoxidil. Users report mixed experiences, with some seeing no side effects and others cautioning about the lack of reliable data on RU58841's safety.

The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

KX-826 is considered effective for hair maintenance, with better safety research than RU58841, but lacks positive anecdotes. RU58841 is seen as potentially stronger, but concerns exist about systemic effects; combining anti-androgens with 5AR inhibitors is suggested for better results.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

The conversation discusses reliable brands for RU58841, with recommendations for RUdirect and Receptorchem. Users also mention Anageninc as a known option for RU58841 in Europe and the UK.

PP405 was ineffective for hair growth as some follicles were already active before treatment, raising doubts about its efficacy. Users discussed other hair loss treatments like Minoxidil, finasteride, and RU58841, expressing skepticism and hope for future solutions.

PP405 is being discussed for hair regrowth, with mixed opinions on its effectiveness and legitimacy. Some users report early signs of regrowth, while others are skeptical about its authenticity and results.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.